Qiong Wu1,2, Qiuhong Wang2, Xin Tang3, Ran Xu1, Luzhong Zhang3, Xinming Chen4, Qun Xue4, Ziheng Wang5,6, Rongfeng Shi7, Feiran Wang8, Fei Ju2, Bo Zhang2, You Lang Zhou2. 1. Medical school, Nantong university, Nantong, P.R. China. 2. The Hand Surgery Research Center, Department of Hand Surgery, Affiliated Hospital of Nantong University, Nantong, P.R. China. 3. Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, P.R. China. 4. Department of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Nantong, P.R. China. 5. Department of Medicine, Nantong University Xinling college, Nantong, Jiangsu, P.R. China. 6. Department of anesthesiology, The First people's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Suzhou, P.R. China. 7. Department of Interventional, Affiliated Hospital of Nantong University, Nantong, P.R. China. 8. Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, P.R. China.
Abstract
Background: Although immunosenescence-induced difference on overall immune function and immune cell subsets between younger and older populations has been well characterized, the potential effect of patients' age on the efficacy of immune checkpoint inhibitors (ICIs) remains little known. We performed a meta-analysis to investigate whether age differences play a role in cancer immunotherapy efficacy based on a large amount of clinical data. Methods: We conducted a systematic search of PubMed, Embase and MEDLINE for relevant randomized controlled trials. The primary outcome was overall survival (OS) and progression-free survival (PFS) was secondary outcome. The interaction test was used to assess the heterogeneity of HR between younger and older groups. Results: In total, 19 clinical randomized trials involving 11157 patients were included. The pooled HR for OS was 0.73 (95% CI 0.69-0.78) and 0.63 (95% CI 0.52-0.73) for PFS in younger patients receiving ICIs treatments, when compared with younger patients treated with controls. For older patients treated with ICIs, the pooled HR for OS compared with controls was 0.64 (95% CI 0.59-0.69) and 0.66 (95% CI 0.58-0.74) for PFS. The difference on OS efficacy between younger and older patients treated with ICIs was significant (Pheterogeneity = 0.025). Conclusions: Immune checkpoint inhibitors significantly improved OS and PFS in both younger and older patients compared with controls, but the magnitude of benefit was clinically age-dependent. Patients ≥65 y can benefit more from immunotherapy than younger patients. Future research should take age difference into consideration in trials and focus on tolerance and toxicity of ICIs in older patients.
Background: Although immunosenescence-induced difference on overall immune function and immune cell subsets between younger and older populations has been well characterized, the potential effect of patients' age on the efficacy of immune checkpoint inhibitors (ICIs) remains little known. We performed a meta-analysis to investigate whether age differences play a role in cancer immunotherapy efficacy based on a large amount of clinical data. Methods: We conducted a systematic search of PubMed, Embase and MEDLINE for relevant randomized controlled trials. The primary outcome was overall survival (OS) and progression-free survival (PFS) was secondary outcome. The interaction test was used to assess the heterogeneity of HR between younger and older groups. Results: In total, 19 clinical randomized trials involving 11157 patients were included. The pooled HR for OS was 0.73 (95% CI 0.69-0.78) and 0.63 (95% CI 0.52-0.73) for PFS in younger patients receiving ICIs treatments, when compared with younger patients treated with controls. For older patients treated with ICIs, the pooled HR for OS compared with controls was 0.64 (95% CI 0.59-0.69) and 0.66 (95% CI 0.58-0.74) for PFS. The difference on OS efficacy between younger and older patients treated with ICIs was significant (Pheterogeneity = 0.025). Conclusions: Immune checkpoint inhibitors significantly improved OS and PFS in both younger and older patients compared with controls, but the magnitude of benefit was clinically age-dependent. Patients ≥65 y can benefit more from immunotherapy than younger patients. Future research should take age difference into consideration in trials and focus on tolerance and toxicity of ICIs in older patients.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: J Clin Epidemiol Date: 2009-07-23 Impact factor: 6.437
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Julia K Tietze; Danice E C Wilkins; Gail D Sckisel; Myriam N Bouchlaka; Kory L Alderson; Jonathan M Weiss; Erik Ames; Kevin W Bruhn; Noah Craft; Robert H Wiltrout; Dan L Longo; Lewis L Lanier; Bruce R Blazar; Doug Redelman; William J Murphy Journal: Blood Date: 2012-01-17 Impact factor: 22.113
Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316
Authors: Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Zhicheng Niu; Shenghu Guo; Jing Cao; Yuehua Zhang; Xiaojin Guo; Francesco Grossi; Yoshinobu Ichiki; You Li; Zhiyu Wang Journal: Ann Transl Med Date: 2021-04
Authors: Benjamin J Murdock; Joshua P Famie; Caroline E Piecuch; Kristen D Raue; Faye E Mendelson; Cole H Pieroni; Sebastian D Iniguez; Lili Zhao; Stephen A Goutman; Eva L Feldman Journal: JCI Insight Date: 2021-06-08
Authors: Fang Yang; Svetomir N Markovic; Julian R Molina; Thorvardur R Halfdanarson; Lance C Pagliaro; Ashish V Chintakuntlawar; Rutian Li; Jia Wei; Lifeng Wang; Baorui Liu; Grzegorz S Nowakowski; Michael L Wang; Yucai Wang Journal: JAMA Netw Open Date: 2020-08-03